Free tool
FAERS Monitor: Caspofungin Acetate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206110 or its brand name (Caspofungin Acetate, Caspofungin Acetate). Reports on generic versions are filed under their own applications.
Reports
1,586
Serious
1,522
96% of reports
Hospitalization
617
Death reported
520
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective372
- off label use99
- multiple organ dysfunction syndrome91
- septic shock74
- death66
- systemic candida65
- drug resistance63
- pneumonia63
- product use in unapproved indication63
- pyrexia62
- febrile neutropenia58
- acute kidney injury56
- pathogen resistance56
- sepsis56
- drug interaction55
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 15 |
| 2006 | 10 |
| 2007 | 23 |
| 2008 | 15 |
| 2009 | 28 |
| 2010 | 42 |
| 2011 | 62 |
| 2012 | 51 |
| 2013 | 34 |
| 2014 | 37 |
| 2015 | 75 |
| 2016 | 50 |
| 2017 | 83 |
| 2018 | 147 |
| 2019 | 145 |
| 2020 | 104 |
| 2021 | 89 |
| 2022 | 110 |
| 2023 | 99 |
| 2024 | 132 |
| 2025 | 127 |
| 2026 | 104 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,573 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| systemic candidaSignal | 65 | 352.5 | 276.9 | 21,852 |
| pathogen resistanceSignal | 56 | 82.0 | 63.3 | 4,374 |
| multiple organ dysfunction syndromeSignal | 91 | 42.7 | 35.0 | 3,661 |
| drug resistanceSignal | 63 | 32.6 | 25.6 | 1,896 |
| septic shockSignal | 74 | 22.6 | 18.1 | 1,506 |
| febrile neutropeniaSignal | 58 | 11.6 | 9.0 | 553 |
| sepsisSignal | 56 | 6.7 | 5.1 | 265 |
| acute kidney injurySignal | 56 | 4.9 | 3.8 | 169 |
| drug interactionSignal | 55 | 4.6 | 3.5 | 152 |
| drug ineffectiveSignal | 372 | 3.7 | 3.4 | 795 |
| product use in unapproved indicationSignal | 63 | 3.4 | 2.6 | 104 |
| pneumoniaSignal | 63 | 2.6 | 2.0 | 60 |
| pyrexiaSignal | 62 | 2.4 | 1.9 | 49 |
| off label use | 99 | 1.5 | 1.2 | 17 |
| death | 66 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.